title: Metformin treatment improves weight and dyslipidemia in children with metabolic syndrome.
abstract: BACKGROUND
  To determine the effects of metformin therapy in children with metabolic syndrome (MS).
  
  
  METHODS
  A retrospective electronic chart review in children aged 8-18 years, from 2000 to 2012 with a diagnosis code for MS (ICD 277.7) that met the modified NCEP ATPIII criteria for MS.
  
  
  RESULTS
  There were a total of 217 subjects, 150 in the non-metformin [untreated group (UTG)] and 67 in the metformin treated group (MTG). At baseline, the MTG had a body mass index (BMI) similar to UTG, but had higher total cholesterol, low-density lipoprotein cholesterol (LDL-C), and non-high density lipoprotein cholesterol (non-HDL-C). At the end of 1 year, the MTG (n=28) had reduced weight percentile (99.4±0.7 vs. 98.9±1.7, p=0.03), BMI percentile (99.2±0.5 vs. 98.8±1.1, p=0.012), total cholesterol (194.9±45.8 vs. 177.9±32.5 mg/dL, p=0.04), LDL-C (128.3±44.7 vs. 113.8±36.0 mg/dL, p=0.04), and non-HDL-C (154.6±45.5 vs. 136.4±35.2 mg/dL, p=0.03) compared to their baseline. The UTG (n=56) did not have any significant change in those parameters.
  
  
  CONCLUSIONS
  Metformin treatment results in significant improvement in BMI, total cholesterol, LDL-C, and non-HDL-C in children with MS.
authors.forename: Diane Q
authors.initials: DQ
authors.lastname: Luong
authors.forename: Robert
authors.initials: R
authors.lastname: Oster
authors.forename: Ambika P
authors.initials: AP
authors.lastname: Ashraf
mesh_terms: D000293:Adolescent; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects*; D002648:Child; D050171:Dyslipidemias / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000188:drug therapy*; D008687:Metformin / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin